25b tabs dosed at 1mg each.

These chemicals have nearly no history of human use prior to 2010 when they first became available online, and very little is known about this group of compounds. They should only be used with extreme caution. It's recommended to not take more than 1.5 mg of any substance of the NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. family, as there have been multiple deaths from people just taking 2-3 blotters.

25I-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. Dosage

Effects have been reported to vary very strongly by person (for example: person A gets a 4-hour body high with barely any visual aspects, while person B gets a >12 hour DOB-like trip with an intense visual aspect). NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. chemicals are not active orallyRoute of administration in which the subject swallows a substance., and will not work if swallowed. It is recommended to avoid sublingual administrationRoute of administration in which the subject places a substance under the tongue. because of the reported bad taste. Buccal administrationRoute of administration in which the subject places a substance against their gums or other oral mucosa. is common, placing the tab between the upper or lower gum and lip.

Sublingual
Light 200-500 μg
Common 500-1500 μg
Strong 1500+ μg
Insufflated
Light 100-400 μg
Common 400-700 μg
Strong 700+ μg+

25C-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. Dosage

Effects have been reported to vary very strongly by person (for example: person A gets a 4-hour body high with barely any visual aspects, while person B gets a >12 hour DOB-like trip with an intense visual aspect).

Sublingual
Light 100-300 μg
Common 300-800 μg
Strong 800+ μg

25B-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. Dosage

Sublingual
Light 100-300 μg
Common 300-500 μg
Strong 500-700+ μg
Insufflated
Light 50-200 μg
Common 200-350 μg
Strong 350-500+ μg

Duration

Sublingual
Onset 15-45 minutes
Total 4-11 hours
Insufflated
Onset 0-10 minutes
Total 3-8 hours

Effects

Positive

  • Strong open and closed eye visuals, including trails, color shifts, brightening, etc.
  • Mood lift
  • Euphoria
  • Mental and physical stimulation
  • Increase in associative & creative thinking
  • Increased awareness & appreciation of music
  • Life-changing spiritual experiences
  • Erotic, sexual thoughts and sensations
  • Feelings of love and empathy

Neutral

  • General change in consciousness
  • Pupil dilation
  • Difficulty focusing
  • Unusual body sensations (facial flushing, chills, goosebumps, body energy)
  • Change in perception of time, time dilation
  • Slight increase in heart rate
  • Yawning, especially when coming up

Negative

Likelihood of negative side effects increases with higher doses.

  • Confusion
  • Looping
  • Scrambled communication
  • Nausea
  • Vasoconstriction
  • Insomnia
  • Looping, recursive, out of control thinking
  • Paranoia, fear, and panic
  • Unwanted and overwhelming feelings
  • Unwanted life-changing spiritual experiences

After effects

  • Afterglow
    • An afterglow may be present until a day after use, sometimes more depending on the individual.
  • Long term effects
    • A relatively high rate of HPPD has been reported (all anecdotal data!) after the use of the NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. chemicals.

Harm Reduction

NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. are considered less safe than many psychedelics, as they generally have a much lower threshold for overdose and have a much heavier physical effect on the body. Even so, many reports of death by an NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. chemical involve mislabeling of the drug (example: someone insufflates 20mg of 25I-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. because he/she thought it was 2C-I). Due the extreme potency and low LD50The dosage of a substance at which 50% of the exposed subjects does not survive. To estimate the LD50 for humans, tests are conducted on non-human subjects. of NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines., mislabeling or misweighing can easily lead to extrmemely dangerous, sometimes lethal, situations. Administration of NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. in its powder form (either insufflated or otherwise) is strongly discouraged, as the potency is far greater than the accuracy of most scales.

Furthermore, due to the physical strain the drug causes one should not use it if there are any pre-existing heart conditions.

See Psychedelic Harm Reduction for general information.

Legal status

Europe

The NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. series of psychoactives became controlled in the Russian Federation] starting October, 2011.[1]

The UK Home Office announced that 25I-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. would be made a class A drug on 10th June 2014 alongside every other N-benzyl phenethylamines.[2]

America

25i-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines., 25b-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines., and 25c-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. were emergency scheduled by the DEA on Novemeber 15, 2013[3]

Images

Links

Wikipedia

Erowid

/r/Drugs FAQ

References

  1. http://www.rg.ru/2011/10/19/narko-dok.html
  2. http://www.legislation.gov.uk/ukdsi/2014/9780111110904
  3. http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml

Top Contributors